About ApiJect
ApiJect is a company based in Stamford (United States) founded in 2015 by Marc Koska and Jay Walker. ApiJect has raised $111 million across 2 funding rounds from investors including Royalty Pharma, Jefferies and DFC. ApiJect offers products and services including Blow-Fill-Seal Container, Apiject Platform, and Prefilled Injector. ApiJect operates in a competitive market with competitors including Exela Pharma, August Bioservices, Gland Pharma, Vetter Pharma and INCOG BioPharma Services, among others.
- Headquarter Stamford, United States
- Founders Marc Koska, Jay Walker
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Apiject Systems, Corp.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$111 M (USD)
in 2 rounds
-
Latest Funding Round
$111 M (USD), Series D
Apr 15, 2022
-
Investors
Royalty Pharma
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ApiJect
ApiJect offers a comprehensive portfolio of products and services, including Blow-Fill-Seal Container, Apiject Platform, and Prefilled Injector.
Aseptic container for prefilled injections ensuring safety and sterility.
Platform simplifying injections for pharmaceuticals and global health use.
Device enabling easy administration by non-professionals in various settings.
People of ApiJect
Unlock access to complete
Funding Insights of ApiJect
ApiJect has successfully raised a total of $111M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $111 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ApiJect
ApiJect has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Royalty Pharma, Jefferies and DFC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Locked | Locked | Locked | |
|
Government agency supporting the development of SMEs
|
Locked | Locked | Locked | |
|
Merger and acquisitions advisory services are provided across multiple sectors.
|
Locked | Locked | Locked |
Investor details for ApiJect
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ApiJect
Investment portfolio details for ApiJect
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ApiJect
Detailed financials for ApiJect
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Apiject Comparisons
Peer comparison for ApiJect
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ApiJect
ApiJect operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Exela Pharma, August Bioservices, Gland Pharma, Vetter Pharma and INCOG BioPharma Services, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sterile injectable pharmaceuticals are manufactured alongside CDMO services.
|
|
| Locked | Locked | Locked |
Diversified research services for clinical solutions are offered.
|
|
| Locked | Locked | Locked |
Generic injectable drugs are manufactured across therapeutic segments.
|
|
| Locked | Locked | Locked |
CDMO specializing in aseptically prefilled syringe systems, cartridges and vials.
|
|
| Locked | Locked | Locked |
Injectable drug products are manufactured by this biopharma CDMO.
|
Detailed competitors of ApiJect
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Apiject
Complete news archive for ApiJect
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ApiJect
ApiJect was founded in 2015 and raised its 1st funding round 5 years after it was founded.
ApiJect is headquartered in Stamford, United States. It is registered at Stamford, Connecticut, United States.
Jay Walker is the current CEO of ApiJect. They have also founded this company.
ApiJect is a funded company, having raised a total of $111M across 2 funding rounds to date.
ApiJect manufacturer of medicine injectors, focusing on providing healthcare solutions, biopharma outsourcing, cdmo, small molecules peptides, formulation, and injectibles. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.
ApiJect's top competitors include Exela Pharma, Gland Pharma and Luoxin Pharmaceutical Group.
ApiJect offers Blow-Fill-Seal Container, Apiject Platform, and Prefilled Injector.
ApiJect has 3 investors. Key investors include Royalty Pharma, Jefferies, and DFC.